Keeping track with the latest developments in legal compliance can often seem like an overwhelming task for legal professionals or insurance administrators. Recently, the Florida Office of Insurance Regulation (OIR) released an Informational Memorandum (“Memorandum”) to Pharmacy Benefit Managers (PBMs), laying out the manner of implementation of certain requirements under the Prescription Drug Reform Act.
The Informational Memorandum OIR-23-04M was issued on July 19, 2023, constituting a key update to Third Party Administrators (TPAs) and PBMs. The Memorandum explained the provisions of the Prescription Drug Reform Act, which is also known as Florida Senate Bill 1550. This legislatively significant bill was signed into law by Florida Governor DeSantis in May 2023.
The Memorandum constitutes an important piece of correspondence to PBMs, delving into the specifics of how the OIR will be implementing the requirements associated with PBMs under the Prescription Drug Reform Act. By releasing this memorandum, the OIR expects to provide guidance to PBMs and to further clarify the stipulations of the Act.
The legislation of the Prescription Drug Reform Act marked a pivotal turning point in Florida’s approach to prescription drug pricing. The Act was designed to drive transparency in pharmaceutical pricing and to ensure fair practices in the field of pharmacy benefits management. Its implementation will likely have an expansive impact on TPAs and PBMs and change the landscape of the pharmacy benefits industry as a whole.
As legal professionals in the field, it’s essential to stay updated with these regulatory shifts to ensure that businesses remain in compliance with the new directives. The Informational Memorandum is available here.